AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer

Monday, AstraZeneca Plc AZN released latest analysis of the results from the DUO-E Phase 3 trial of Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) in mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone.

The data demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone.

A post-hoc exploratory subgroup analysis assessed patients by mismatch repair (MMR) status, a biomarker of interest in endometrial cancer. 

In this analysis, the median duration of response (DoR) in pMMR patients in the Lynparza and Imfinzi arm was more than double versus the control arm (18.7 months versus 7.6). 

Additional secondary endpoints showed consistent results for pMMR patients treated with Lynparza and Imfinzi, demonstrating a reduction in the risk of second progression or death (PFS2) by 32% for the combination versus the control arm (median not reached versus 19.5 months), and improvement in time to first and second subsequent treatments.

Imfinzi plus chemotherapy followed by Imfinzi monotherapy (Imfinzi arm) showed consistent benefit regardless of MMR status, with the greatest benefit observed in patients with mismatch repair deficient (dMMR) disease across all secondary endpoints, including objective response rate (ORR) (71.4%) and DoR (median not reached), versus the control arm (40.5% and 10.5 months, respectively).

In the overall trial population, results in the Lynparza and Imfinzi arm showed extended ORR and DoR, as well as consistently improved benefit in secondary endpoints, including overall survival (OS), time to first subsequent therapy, PFS2, and time to second subsequent therapy.

Concurrently, AstraZeneca announced that starting June 1, 2024, eligible patients will pay no more than $35 per month for all AstraZeneca U.S. inhaled respiratory medicines, including:

• Airsupra (albuterol and budesonide) 
• Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) Inhalation Aerosol 
• Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) Inhalation Aerosol 
• Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol 

Price Action: AZN shares are down 0.24% at $66.15 on the last check Monday.

Illustration of Phrama lab worker created with MidJourney.